EUDA
EUDA Health Holdings Limited
There isn't enough reported data to score EUDA yet.
EUDA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
EUDA's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
EUDA PE Valuation
EUDA has no meaningful PE right now: it lost money over the past year.
EUDA Forward outlook
There aren't enough analyst estimates for EUDA to show an outlook.
EUDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.23 | -$1.11 |
| Q1 2026 | -$2.40 | +$4.40 |
| Q4 2025 | -$2.56 | +$9.92 |
| Q3 2025 | -$1.31 | +$11.43 |
EUDA is still losing money, but far less than before: $2.23 per share over the past year, against $46.80 at its worst in mid-2023.
EUDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.7M | +13% |
| Q1 2026 | $1.7M | +13% |
| Q4 2025 | $6.8M | +549% |
| Q3 2025 | $1.9M | +79% |
| Q2 2025 | $1.5M | +60% |
| Q1 2025 | $1.5M | +60% |
| Q4 2024 | $1.1M | +10% |
| Q2 2024 | $954K | -14% |
EUDA's revenue has grown year over year for seven quarters in a row: $2M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -22% | +15 points |
| Q1 2026 | -22% | +15 points |
| Q4 2025 | -36% | +11 points |
| Q3 2025 | -36% | +11 points |
| Q2 2025 | -37% | +820 points |
| Q1 2025 | -37% | +820 points |
| Q4 2024 | -47% | +18 points |
| Q3 2024 | -47% | N/A |
EUDA's operating margin was −22% last quarter, up 15 points from the same quarter a year ago.
EUDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$603K | +$16.3K |
| Q1 2026 | -$603K | +$16.3K |
| Q4 2025 | -$2.5M | -$2.1M |
| Q3 2025 | -$632.6K | -$196.7K |
| Q2 2025 | -$619.3K | +$10.6K |
| Q1 2025 | -$619.3K | +$10.6K |
| Q4 2024 | -$435.9K | -$65.7K |
| Q2 2024 | -$629.9K | -$629.9K |
EUDA has burned cash in most quarters: −$4M over the past year, against −$2M the year before.
EUDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +31% | +572K shares |
| 3 years | +141% | +1.4M shares |
| 5 years | +555% | +2.1M shares |
EUDA has 2M diluted shares, up 31% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
EUDA hasn't bought back shares in the past year.
EUDA Net Leverage
EUDA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EUDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 42.3 | Neutral |
EUDA's weekly RSI is 49 (neutral) and its Stochastic is 42 (neutral).
EUDA PE vs Healthcare Sector
EUDA has no meaningful PE right now: it lost money over the past year.
EUDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.1 | 1.9% below |
| 20 week MA | $15.1 | 4.6% above |
| 50 week MA | $19.8 | 20% below |
| 100 week MA | $43.0 | 63% below |
| 200 week MA | $42.8 | 63% below |
EUDA's trend is mixed: it's above one of its five weekly moving averages, and 63% below its 200-week average.
EUDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $193.4 | $194.4 | +0.5% |
| 2022 | $194.4 | $36.6 | -81% |
| 2023 | $36.6 | $28.6 | -22% |
| 2024 | $28.6 | $91.4 | +220% |
| 2025 | $91.4 | $49.0 | -46% |
| 2026 YTD | $49.0 | $15.8 | -68% |
EUDA's yearly returns have swung widely, from +220% in 2024 to −81% in 2022. It's down 68% so far in 2026.